Literature DB >> 21994352

Immunochromatographic IgG/IgM test for rapid diagnosis of active tuberculosis.

Walid Ben-Selma1, Hedi Harizi, Jalel Boukadida.   

Abstract

For rapid diagnosis and discrimination between active tuberculosis (TB) and other pulmonary diseases, we evaluated the clinical usefulness of detection of serum immunoglobulin IgG and IgM antibodies raised against mycobacterial 38-kDa, 16-kDa, and 6-kDa antigens by a commercial rapid immunochromatographic IgG/IgM test (Standard Diagnostics, South Korea) in 246 serum samples from three groups of patients: (i) 171 patients with active TB (128 with pulmonary TB [pTB] and 43 with extrapulmonary TB [epTB]), (ii) 73 patients with pulmonary non-TB diseases, and (iii) two leprosy patients. The sensitivities of IgG and IgM in patients with active TB (pTB and epTB) were 68.4% and 2.3%, respectively. IgG had the best performance characteristics, with sensitivities of 78.1% and 39.5% in sera from patients with active pTB and epTB, respectively, and a specificity of 100%. The sensitivities of IgM were poor and were similar for pTB and epTB (2.3%). In contrast, specificity was very elevated (100%). The combination of IgG with IgM did not improve its sensitivity. IgG-mediated responses against the mycobacterial 38-kDa, 16-kDa, and 6-kDa antigens might constitute a clinically useful tool for presumptive diagnosis and discrimination of active pTB from other pulmonary diseases. Moreover, based on its simplicity and rapidity of application, it could be a screening tool for active pTB in poorly equipped laboratories.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21994352      PMCID: PMC3232703          DOI: 10.1128/CVI.05166-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  39 in total

Review 1.  Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

2.  Smear-negative pulmonary tuberculosis in industrialized countries.

Authors:  R Long
Journal:  Chest       Date:  2001-08       Impact factor: 9.410

3.  Mass spectrometric identification of mtb81, a novel serological marker for tuberculosis.

Authors:  R C Hendrickson; J F Douglass; L D Reynolds; P D McNeill; D Carter; S G Reed; R L Houghton
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

4.  Accuracy and utility of commercially available amplification and serologic tests for the diagnosis of minimal pulmonary tuberculosis.

Authors:  K Al Zahrani; H Al Jahdali; L Poirier; P René; M L Gennaro; D Menzies
Journal:  Am J Respir Crit Care Med       Date:  2000-10       Impact factor: 21.405

5.  Humoral immune response against 38-kDa and 16-kDa mycobacterial antigens in bone and joint tuberculosis.

Authors:  U Demkow; T M Zielonka; M Nowak-Misiak; M Filewska; B Bialas; J Strzalkowski; K Rapala; Z Zwolska; E Skopinska-Rozewska
Journal:  Int J Tuberc Lung Dis       Date:  2002-11       Impact factor: 2.373

6.  Spectrum of immune response abnormalities in different clinical forms of tuberculosis.

Authors:  R Bhatnagar; A N Malaviya; S Narayanan; P Rajgopalan; R Kumar; O P Bharadwaj
Journal:  Am Rev Respir Dis       Date:  1977-02

7.  Uncommon presentations of tuberculosis: the potential value of a novel diagnostic assay based on the Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10.

Authors:  S M Arend; T H Ottenhoff; P Andersen; J T van Dissel
Journal:  Int J Tuberc Lung Dis       Date:  2001-07       Impact factor: 2.373

8.  The immune spectrum in patients with pulmonary tuberculosis.

Authors:  T M Daniel; M J Oxtoby; E Pinto; E Moreno
Journal:  Am Rev Respir Dis       Date:  1981-05

Review 9.  A review of the diagnosis and treatment of smear-negative pulmonary tuberculosis.

Authors:  R Colebunders; I Bastian
Journal:  Int J Tuberc Lung Dis       Date:  2000-02       Impact factor: 2.373

10.  Factors associated with humoral response to ESAT-6, 38 kDa and 14 kDa in patients with a spectrum of tuberculosis.

Authors:  V M C Silva; G Kanaujia; M L Gennaro; D Menzies
Journal:  Int J Tuberc Lung Dis       Date:  2003-05       Impact factor: 2.373

View more
  7 in total

1.  Evaluation of antigen-specific immunoglobulin g responses in pulmonary tuberculosis patients and contacts.

Authors:  Yun-Gyoung Hur; Ahreum Kim; Young Ae Kang; An Sik Kim; Dae Yeon Kim; Yeun Kim; Youngmi Kim; Hyeyoung Lee; Sang-Nae Cho
Journal:  J Clin Microbiol       Date:  2015-01-14       Impact factor: 5.948

2.  T7 Phage Display Library a Promising Strategy to Detect Tuberculosis Specific Biomarkers.

Authors:  Harvinder Talwar; Jaya Talreja; Lobelia Samavati
Journal:  Mycobact Dis       Date:  2016-06-28

3.  A systematic review of biomarkers to detect active tuberculosis.

Authors:  Emily MacLean; Tobias Broger; Seda Yerlikaya; B Leticia Fernandez-Carballo; Madhukar Pai; Claudia M Denkinger
Journal:  Nat Microbiol       Date:  2019-02-25       Impact factor: 17.745

4.  Theoretical and Experimental Comparison of Different Formats of Immunochromatographic Serodiagnostics.

Authors:  Dmitriy V Sotnikov; Anatoly V Zherdev; Boris B Dzantiev
Journal:  Sensors (Basel)       Date:  2017-12-25       Impact factor: 3.576

Review 5.  CRISPR-based assays for rapid detection of SARS-CoV-2.

Authors:  Vivek S Javalkote; Nagesh Kancharla; Bhaskar Bhadra; Manish Shukla; Badrish Soni; Ajit Sapre; Michael Goodin; Anindya Bandyopadhyay; Santanu Dasgupta
Journal:  Methods       Date:  2020-10-10       Impact factor: 4.647

6.  Lateral Flow Serodiagnosis in the Double-Antigen Sandwich Format: Theoretical Consideration and Confirmation of Advantages.

Authors:  Dmitriy V Sotnikov; Anatoly V Zherdev; Boris B Dzantiev
Journal:  Sensors (Basel)       Date:  2020-12-23       Impact factor: 3.576

7.  Silent Antibodies Start Talking: Enhanced Lateral Flow Serodiagnosis with Two-Stage Incorporation of Labels into Immune Complexes.

Authors:  Dmitriy V Sotnikov; Nadezhda A Byzova; Anatoly V Zherdev; Youchun Xu; Boris B Dzantiev
Journal:  Biosensors (Basel)       Date:  2022-06-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.